10 Jun Bio-Me´s technology demonstrates its usefulness in metabolic syndrome research in a Lancet publication

PMP™, Bio-Me´s microbiome analysis platform, was used to show that Ruminococcus gnavus is a major independent predictor of obesity in a study published in The Lancet.

OSLO, Norway, June 10, 2022 – A recent study investigated the association between the gut microbiome and features of the metabolic syndrome. In the study, a total of 5215 fecal samples from the population-wide HUNT Biobank in Norway were analyzed with Bio-Me’s Precision Microbiome Profiling (PMP™) platform for determining the absolute quantification of 50 prevalent and well-characterized gut microbes.

The study demonstrated that the presence of the Ruminococcus gnavus species is a reproducible and major independent predictor of several features of the metabolic syndrome, such as percent body fat, serum triglycerides, waist circumference, CRP, and HbA1c. All associations remained after adjusting for multiple well-known confounders and reverse causality. What is unique about the study is the large population size and the fact that the data was consistent over three cohorts.

The study was conducted in a collaboration between researchers from the University of Gothenburg, Karolinska Institutet, Norwegian University of Science and Technology, HUNT Research Centre, and Bio-Me.

Warren Flood, CEO of Bio-Me, states: “We are thrilled to see this major publication coming out of our fruitful collaboration with the HUNT Research Centre and the University of Gothenburg. The study demonstrates the usefulness of PMP™, a validated platform for determining the absolute abundance of target organisms, and for cost-effective high throughput microbiome profiling as seen in this study. We are grateful for the opportunity to work with these world-leading institutions in validating our technology”.

Link to the publication: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00113-9/fulltext#%20.